Cargando…

Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates

[Image: see text] (R)-[(11)C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[(11)C]verapamil in rats and humans under different conditions. However, to the be...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Varela, Lara, García, David Vállez, Kakiuchi, Takeharu, Ohba, Hiroyuki, Nishiyama, Shingo, Tago, Tetsuro, Elsinga, Philip H., Tsukada, Hideo, Colabufo, Nicola A., Dierckx, Rudi A.J.O., van Waarde, Aren, Toyohara, Jun, Boellaard, Ronald, Luurtsema, Gert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788571/
https://www.ncbi.nlm.nih.gov/pubmed/33315404
http://dx.doi.org/10.1021/acs.molpharmaceut.0c01014
_version_ 1783633055540314112
author García-Varela, Lara
García, David Vállez
Kakiuchi, Takeharu
Ohba, Hiroyuki
Nishiyama, Shingo
Tago, Tetsuro
Elsinga, Philip H.
Tsukada, Hideo
Colabufo, Nicola A.
Dierckx, Rudi A.J.O.
van Waarde, Aren
Toyohara, Jun
Boellaard, Ronald
Luurtsema, Gert
author_facet García-Varela, Lara
García, David Vállez
Kakiuchi, Takeharu
Ohba, Hiroyuki
Nishiyama, Shingo
Tago, Tetsuro
Elsinga, Philip H.
Tsukada, Hideo
Colabufo, Nicola A.
Dierckx, Rudi A.J.O.
van Waarde, Aren
Toyohara, Jun
Boellaard, Ronald
Luurtsema, Gert
author_sort García-Varela, Lara
collection PubMed
description [Image: see text] (R)-[(11)C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[(11)C]verapamil in rats and humans under different conditions. However, to the best of our knowledge, the pharmacokinetics of (R)-[(11)C]verapamil have not yet been evaluated in nonhuman primates. Our study aims to establish (R)-[(11)C]verapamil as a reference P-gp tracer for comparison of a newly developed P-gp positron emission tomography (PET) tracer in a species close to humans. Therefore, the study assesses the kinetics of (R)-[(11)C]verapamil and evaluates the effect of scan duration and P-gp inhibition on estimated pharmacokinetic parameters. Three nonhuman primates underwent two dynamic 91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The (R)-[(11)C]verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations (10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors (SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the (R)-[(11)C]verapamil data at baseline and after inhibition and for all scan durations tested. The volume of distribution (V(T)) and the efflux constant k(2) estimations were affected by the evaluated scan durations, whereas the influx constant K(1) estimations remained relatively constant. After P-gp inhibition (tariquidar, 8 mg/kg), in a 91 min scan duration, the whole-brain V(T) increased significantly up to 208% (p < 0.001) and K(1) up to 159% (p < 0.001) compared with baseline scans. The k(2) values decreased significantly after P-gp inhibition in all the scan durations except for the 91 min scans. This study suggests the use of K(1), calculated with 1-TCM and using short PET scans (10 to 30 min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates.
format Online
Article
Text
id pubmed-7788571
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-77885712021-01-07 Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates García-Varela, Lara García, David Vállez Kakiuchi, Takeharu Ohba, Hiroyuki Nishiyama, Shingo Tago, Tetsuro Elsinga, Philip H. Tsukada, Hideo Colabufo, Nicola A. Dierckx, Rudi A.J.O. van Waarde, Aren Toyohara, Jun Boellaard, Ronald Luurtsema, Gert Mol Pharm [Image: see text] (R)-[(11)C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[(11)C]verapamil in rats and humans under different conditions. However, to the best of our knowledge, the pharmacokinetics of (R)-[(11)C]verapamil have not yet been evaluated in nonhuman primates. Our study aims to establish (R)-[(11)C]verapamil as a reference P-gp tracer for comparison of a newly developed P-gp positron emission tomography (PET) tracer in a species close to humans. Therefore, the study assesses the kinetics of (R)-[(11)C]verapamil and evaluates the effect of scan duration and P-gp inhibition on estimated pharmacokinetic parameters. Three nonhuman primates underwent two dynamic 91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The (R)-[(11)C]verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations (10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors (SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the (R)-[(11)C]verapamil data at baseline and after inhibition and for all scan durations tested. The volume of distribution (V(T)) and the efflux constant k(2) estimations were affected by the evaluated scan durations, whereas the influx constant K(1) estimations remained relatively constant. After P-gp inhibition (tariquidar, 8 mg/kg), in a 91 min scan duration, the whole-brain V(T) increased significantly up to 208% (p < 0.001) and K(1) up to 159% (p < 0.001) compared with baseline scans. The k(2) values decreased significantly after P-gp inhibition in all the scan durations except for the 91 min scans. This study suggests the use of K(1), calculated with 1-TCM and using short PET scans (10 to 30 min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates. American Chemical Society 2020-12-14 2021-01-04 /pmc/articles/PMC7788571/ /pubmed/33315404 http://dx.doi.org/10.1021/acs.molpharmaceut.0c01014 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle García-Varela, Lara
García, David Vállez
Kakiuchi, Takeharu
Ohba, Hiroyuki
Nishiyama, Shingo
Tago, Tetsuro
Elsinga, Philip H.
Tsukada, Hideo
Colabufo, Nicola A.
Dierckx, Rudi A.J.O.
van Waarde, Aren
Toyohara, Jun
Boellaard, Ronald
Luurtsema, Gert
Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates
title Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates
title_full Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates
title_fullStr Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates
title_full_unstemmed Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates
title_short Pharmacokinetic Modeling of (R)-[(11)C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates
title_sort pharmacokinetic modeling of (r)-[(11)c]verapamil to measure the p-glycoprotein function in nonhuman primates
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788571/
https://www.ncbi.nlm.nih.gov/pubmed/33315404
http://dx.doi.org/10.1021/acs.molpharmaceut.0c01014
work_keys_str_mv AT garciavarelalara pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT garciadavidvallez pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT kakiuchitakeharu pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT ohbahiroyuki pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT nishiyamashingo pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT tagotetsuro pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT elsingaphiliph pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT tsukadahideo pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT colabufonicolaa pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT dierckxrudiajo pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT vanwaardearen pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT toyoharajun pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT boellaardronald pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates
AT luurtsemagert pharmacokineticmodelingofr11cverapamiltomeasurethepglycoproteinfunctioninnonhumanprimates